Information letter regarding Anemet® 200 mg tablets (dolasetron): Discontinuation of production
2011.04.26
Active substance: dolasetron
Due to the risk of arrhythmias in connection with the administration of Anemet® 200 mg tablets to adults for prevention and treatment of nausea and vomiting associated with cytostatic chemotherapy, the pharmaceutical manufacturer has renounced this indication as a precautionary measure on its own responsibility. Production will be discontinued.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN